CVS Healthの空売り状況は、投資家がCVS Healthの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

CVS Health (NYSE:CVS) 株価情報, 空売り情報

CVS HEALTH CORP

CVS Health

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.

CVS Health Corp

Morgan Stanley ETF Trust Calvert Ultra-Short Investment Grade ETF

CARDIOVASCULAR SCI INC by Cardiovascular Sciences, Inc.

Morgan Stanley ETF Trust Calvert US Select Equity ETF

CVS Group PLC

CIVITAS SOCIAL HSG PLC by CIVITAS SOCIAL HSG PLC

CV Sciences Inc

COVISTA COMMUNS INC by Covista Communications, Inc,

Covista Communications Inc

CONVERGENCE SYS INC CL A by Convergence Systems Inc.

Convergence Systems Inc

<p>In September, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—<strong>CVS Health Inc&#8217;s</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark, <strong>Cigna Corp&#8217;s</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts, and <strong>UnitedHealth Group Inc&#8217;s</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">price of insulin medications</a>.</p>
<p>The&nbsp;complaint&nbsp;accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">prescriptions in the U.S</a>.</p>
<p>The FTC is now pausing after the agency submitted <a href="https://www.ftc.gov/system/files/ftc_gov/pdf/d9437_2025.04.01_commorderstayingadjudication.pdf" target="_blank" rel="noreferrer noopener">an order</a> seeking an administrative stay in the case.</p>
<p><strong>Also Read:<a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43010888/ftc-says-unitedhealth-cvs-cigna-make-billions-via-pbms-on-specialty-drugs" rel="noreferrer noopener"> FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs</a></strong></p>
<p>The agency does not cite any sitting commissioners who can join the proceedings. The two sitting commissioners, Republicans <strong>Andrew Ferguson</strong> and <strong>Melissa Holyoak</strong>, <a href="https://www.benzinga.com/government/24/10/41172976/texas-attorney-general-sues-insulin-manufacturers-and-pharmacy-benefit-managers-over-price-fixing-co" target="_blank" rel="noreferrer noopener">have recused themselves</a>.</p>
<p>According to the order filed this week, the stay will remain in place for at least 105 days. The courts also set an evidentiary hearing for 225 days after the stay lifts.</p>
<p>Reuters notes that of its five sitting commissioners, two were fired, two were removed from the case, and one resigned when Trump took office.</p>
<p>Several state and local governments also filed lawsuits against drug companies and pharmacy benefit managers, accusing them <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40560002/governments-suing-pharmacy-benefit-managers-over-insulin-prices-have-long-benefited-from-their-r" rel="noreferrer noopener">of inflating insulin prices</a>.</p>
<p>In November 2024, the FTC faced legal challenges from three competing pharmacy-benefit managers over its attempt to restrict their ability to negotiate drug prices for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system" rel="noreferrer noopener">health plan sponsors</a>.</p>
<p>The PBMs argue that this action seeks to upend current drug rebate contracts and disrupt long-standing practices, all while expanding the FTC&#8217;s authority beyond traditional limits.</p>
<p>The companies also&nbsp;contend&nbsp;that the administrative proceeding violates constitutional principles by lacking independent judicial oversight and claim that the FTC&#8217;s approach could result in significant and irreparable injury.</p>
<p><strong>Price Action: </strong>CI stock is down 1.13% at $328.16, UNH stock is up 0.04% at $523.40, and CVS stock is down 0.85% at $67.49&nbsp;during the premarket session at the last check Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/04/44614073/sportradars-big-bet-on-sports-data-analyst-raises-2026-forecast-sees-major-growth-in-live-betting" target="_blank" rel="noreferrer noopener">Sportradar&#8217;s Bets Big On Sports Data, Analyst Says Company Has Favorable Setup</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Large Cap

News

Health Care

Legal

General

FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth's PBMs Amid Commissioner Shortage

<p>The <strong>S&amp;P 500 Index</strong> just finished a vicious <a href="https://www.benzinga.com/topic/s-p-500">first quarter of 2025</a>.</p>
<p>The stock market index lost over 4.5% as investor sentiment, as indicated by the CNN Money Fear and Greed Index, languishes in the <a href="https://www.benzinga.com/25/04/44601155/sp-500-settles-higher-ahead-of-tariff-day-fear-greed-index-remains-in-extreme-fear-zone">&#8220;Extreme Fear&#8221; category</a>. </p>
<p>The widely held SPX fell into correction territory earlier this week, indicating a 10% drop from its recent high, before regaining some ground.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/03/44547975/sticky-inflation-weighs-on-markets-spy-qqq-tech-stocks-take-a-hit">Sticky Inflation Weighs On Markets — SPY, QQQ, Tech Stocks Take A Hit</a></strong></p>
<p>As one of the most widely used proxies for the SPX, the <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 3.76% this year as of writing. However, <a href="https://www.benzinga.com/etfs">in the ETF</a>, some stocks defied the trend:</p>
<ul>
<li><strong>CVS Health</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) jumped 53.35% due to robust earnings growth in the last quarter. </li>
<li>Gold miner <strong>Newmont Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) rose 26.21%, and </li>
<li><strong>Philip Morris International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) spiked 29% as it shifted its focus to smoke-free products.</li>
</ul>
<p><strong>Also Read: <a href="https://www.benzinga.com/trading-ideas/25/04/44597684/exclusive-marchs-20-most-searched-tickers-on-benzinga-pro-where-do-tesla-nvidia-apple-applovin-stock-rank">EXCLUSIVE &#8211; March&#8217;s 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank?</a></strong></p>
<p>Markets are gearing up for even more turbulence as President <strong>Donald Trump</strong> unveiled a comprehensive slate of tariffs. Watch the stream below.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Trump Speaks Live From The White House on Liberation Day &#x7C; April 2nd, 2025" width="500" height="281" src="https://www.youtube.com/embed/wgmKYg-zK9o?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p>Investors worry that these tariffs, potentially imposed widely on trading partners from China to Mexico and Canada, will raise costs, restrict consumer purchases, and temper economic growth. </p>
<p>With economic news, Federal Reserve actions, and geopolitical tensions front and center, the SPX continues on uncertain footing. </p>
<p>Investors will closely monitor how the market responds to Trump&#8217;s tariff declaration and whether defensive sectors continue to outperform in an increasingly uncertain economic climate.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44613351/chipotles-stock-is-sizzling-bill-ackman-loves-it-and-these-etfs-do-too">Chipotle&#8217;s Stock Is Sizzling—Bill Ackman Loves It And These ETFs Do Too</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Broad U.S. Equity ETFs

ETFs

SPX Nosedives 4.5%: Can ETFs Like SPY Weather The Market Storm?

<p>Deep-pocketed investors have adopted a bullish approach towards CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for CVS Health. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 62% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $132,526, and 5 are calls, amounting to $421,821.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $70.0 for CVS Health, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CVS Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CVS Health's significant trades, within a strike price range of $30.0 to $70.0, over the past month.</p>
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742919439_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.95</td>
<td>$5.85</td>
<td>$5.9</td>
<td>$62.50</td>
<td>$259.6K</td>
<td>4.1K</td>
<td align="right">0</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$1.12</td>
<td>$1.11</td>
<td>$1.12</td>
<td>$60.00</td>
<td>$53.5K</td>
<td>61</td>
<td align="right">439</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.0</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$62.50</td>
<td>$48.7K</td>
<td>4.1K</td>
<td align="right">750</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$2.76</td>
<td>$2.66</td>
<td>$2.73</td>
<td>$65.00</td>
<td>$48.5K</td>
<td>2.8K</td>
<td align="right">237</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.85</td>
<td>$0.83</td>
<td>$0.85</td>
<td>$70.00</td>
<td>$42.5K</td>
<td>3.5K</td>
<td align="right">646</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<h3>Where Is CVS Health Standing Right Now?</h3>
<ul>
<li>With a volume of 3,195,679, the price of CVS is down -1.4% at $66.62. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>What Analysts Are Saying About CVS Health</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $74.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on CVS Health, maintaining a target price of $74. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for CVS Health, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

CVS Health Unusual Options Activity

<p><strong>CVS Health's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has fallen 12.83% since its last report. The company recently reported that it has <strong>20.55 million shares sold short</strong>, which is 1.63% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.15 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742918427_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for CVS Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 9.72%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

Is CVS Health Gaining or Losing Market Support?

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.</p>
<h3 class="wp-block-heading"><strong>DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 4.11%</li>
<li><strong>Mizuho </strong>analyst Steven Valiquette maintained a Neutral rating and cut the price target from $21 to $18 on March 13, 2025. This analyst has an accuracy rate of 60%.</li>
<li><strong>Morgan Stanley </strong>analyst Erin Wright maintained an Overweight rating and cut the price target from $30 to $23 on Dec. 17, 2024. This analyst has an accuracy rate of 76%.</li>
<li><strong>Recent News:</strong> On March 17, Dentsply Sirona named David Ferguson as Global Business Unit Leader.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">XRAY news</a>. </li>
</ul>
<p><figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/6dde7dcc-8523-415e-8b9a-848a09b31f98" alt="" style="width:509px;height:auto" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 4.06%</li>
<li><strong>Wells Fargo </strong>analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 73%.</li>
<li><strong>Cantor Fitzgerald </strong>analyst Olivia Brayer maintained a Neutral rating and increased the price target from $50 to $55 on Feb. 4, 2025. This analyst has an accuracy rate of 63%.</li>
<li><strong>Recent News:</strong> On March 14, the European Commission (EC) approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy..</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<h3 class="wp-block-heading"><strong>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield: </strong>3.97%</li>
<li><strong>Truist Securities </strong>analyst David Macdonald maintained a Buy rating and raised the price target from $60 to $76 on Feb. 13, 2025. This analyst has an accuracy rate of 67%.</li>
<li><strong>Leerink Partners </strong>analyst Michael Cherny upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $75 on Feb. 13, 2025. This analyst has an accuracy rate of 79%.</li>
<li><strong>Recent News: </strong>On March 20, CVS Health reported its board of directors has approved a quarterly dividend of 66.5 cents per share on the Common Stock of the Corporation.</li>
<li><strong>Edge Stock Ratings:</strong> 62.89 Momentum score with Value at 40.46.     <a href="https://www.benzinga.com/quote/CCU" target="_blank" rel="noreferrer noopener"></a></li>
</ul>

<p><figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="470" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24060244/image-217.png" alt="" class="wp-image-838055" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24060244/image-217.png 470w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24060244/image-217-300x120.png 300w" sizes="(max-width: 470px) 100vw, 470px" /></figure></p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p>Want Edge Stock Rankings on this stock?&nbsp;<a href="https://www.benzinga.com/quote/CELH" target="_blank" rel="noreferrer noopener">Become an Edge subscriber here</a></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/03/44434941/how-to-earn-500-a-month-from-kb-home-stock-ahead-of-q1-earnings">How To Earn $500 A Month From KB Home Stock Ahead Of Q1 Earnings</a></strong></li>
</ul>


Dividends

Price Target

Pre-Market Outlook

Analyst Ratings

XRAY

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

<p>8 analysts have expressed a variety of opinions on CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $72.12, a high estimate of $81.00, and a low estimate of $60.00. Surpassing the previous average price target of $66.62, the current average has increased by 8.26%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742562041_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive CVS Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CVS Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of CVS Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CVS Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on CVS Health analyst ratings.</strong></a></p>
<h2>Get to Know CVS Health Better</h2>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<h3>A Deep Dive into CVS Health's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> CVS Health displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>4.15%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>1.68%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> CVS Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>2.18%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> CVS Health's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.65%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> CVS Health's debt-to-equity ratio is below the industry average. With a ratio of <b>1.1</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into CVS Health Stock: Analyst Perspectives (8 Ratings)

<p>Piper Sandler  analyst Jessica Tassan   maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and raises the price target from $72 to $74.</p>


Piper Sandler Maintains Overweight on CVS Health, Raises Price Target to $74

<p>Deep-pocketed investors have adopted a bearish approach towards CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for CVS Health. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 62% bearish. Among these notable options, 2 are puts, totaling $104,108, and 6 are calls, amounting to $535,103.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $70.0 for CVS Health over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CVS Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CVS Health's significant trades, within a strike price range of $60.0 to $70.0, over the past month.</p>
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742408155_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.75</td>
<td>$9.15</td>
<td>$9.75</td>
<td>$65.00</td>
<td>$195.0K</td>
<td>5.6K</td>
<td>0</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$7.65</td>
<td>$7.05</td>
<td>$7.17</td>
<td>$60.00</td>
<td>$167.7K</td>
<td>13.3K</td>
<td>242</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.33</td>
<td>$1.28</td>
<td>$1.27</td>
<td>$65.00</td>
<td>$63.5K</td>
<td>4.2K</td>
<td>3.5K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.75</td>
<td>$2.73</td>
<td>$2.73</td>
<td>$67.50</td>
<td>$58.6K</td>
<td>8.6K</td>
<td>299</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.4</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$70.00</td>
<td>$44.2K</td>
<td>5.1K</td>
<td>208</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<h3>Where Is CVS Health Standing Right Now?</h3>
<ul>
<li>With a volume of 2,662,555, the price of CVS is down -0.11% at $67.5. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 42 days.</li>
</ul>
<h3>What Analysts Are Saying About CVS Health</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $81.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on CVS Health with a target price of $81. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CVS Health options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


This Is What Whales Are Betting On CVS Health

<p><strong>CVS Health Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) is flashing a bullish signal as it completes <a href="https://www.benzinga.com/topic/golden-cross">a <strong>Golden Cross</strong></a> — an event where the 50-day simple moving average (SMA) rises above the 200-day SMA. </p>
<p>With the stock up over 51% year to date and continuing to trade above key moving averages, technicals suggest further upside.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="618" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17133310/Screenshot-2025-03-17-at-5.08.30-PM.png" alt="" class="wp-image-827853" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17133310/Screenshot-2025-03-17-at-5.08.30-PM.png 618w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17133310/Screenshot-2025-03-17-at-5.08.30-PM-300x236.png 300w" sizes="(max-width: 618px) 100vw, 618px" /></a></figure></p>
<p><em><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a></em></p>
<p>Adding to investor enthusiasm, CVS's weight management program has delivered an average 15% weight loss for participants while cutting costs by 26%.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com//node/44346604">Allegations of Inflated Prescription Drug Costs Spark Employee Lawsuit Against JPMorgan</a></strong></p>
<h2 class="wp-block-heading">CVS Stock Technicals Point To Strength</h2>
<p>Several technical signals confirm CVS stock's strong uptrend:</p>
<ul>
<li><strong>Golden Cross Formation</strong>: The 50-day SMA ($57.86) has officially crossed above the 200-day SMA ($57.72), reinforcing a bullish outlook.</li>
<li><strong>Momentum Stays Strong</strong>: CVS stock trades above its eight-day, 20-day and 50-day SMAs, confirming sustained buying pressure.</li>
<li><strong>Moving Average Covergence/Divergence (MACD) Indicator</strong>: At 2.01, the MACD remains in bullish territory, signaling strong upward momentum.</li>
<li><strong>Relative Strength Index (RSI): </strong>The RSI at 62.46, is nearing overbought territory, indicating that CVS stock remains in a strong trend, though some profit-taking could occur.</li>
</ul>
<h2 class="wp-block-heading">CVS Weight Loss Program Gains Traction</h2>
<p>On the fundamental side, CVS reported that its Weight Management program led to an average 15% weight loss among participants and a 26% reduction in weight-loss drug costs. The program, which integrates GLP-1 medications with personalized nutrition plans, has been rolled out to 3.5 million members.</p>
<p>CVS stock has been riding this wave of positive news and strong technicals. The golden cross suggests continued bullish momentum, though with RSI creeping higher, short-term volatility could emerge. If buying pressure remains, CVS could see further gains in the coming weeks.</p>
<p><strong>Related: </strong></p>
<ul>
<li><a href="https://www.benzinga.com//node/44336874"><strong>CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants</strong></a></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Technicals

Signals

Tech

CVS Stock Flashes Golden Cross As Weight Loss Program Delivers Big Results

<p>A lawsuit has been lodged against&nbsp;<strong>JPMorgan Chase &amp; Co.</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) by its employees, who claim that the company&#8217;s prescription drug plan, overseen by&nbsp;<strong>CVS Health Corp.</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), consented&nbsp;to pay exorbitant prices for&nbsp;medications.</p>
<p><strong>What Happened</strong>: According to a report, the lawsuit alleges that JPMorgan mishandled health benefits. One example cited in the case shows the plan paying over&nbsp;$6,000 for a multiple sclerosis&nbsp;drug that could be purchased for approximately $30 at retail pharmacies. </p>
<p>The plaintiffs, which&nbsp;include one current and two&nbsp;former employees, contend that this &#8220;systematic mismanagement&#8221; resulted in &#8220;grossly inflated&#8221; medication costs for those enrolled in the plan.</p>
<p>According to the report <a href="https://www.bloomberg.com/news/articles/2025-03-13/jpmorgan-employee-lawsuit-says-bank-overpaid-for-prescription-drugs?sref=TBDibEcD">by</a> Bloomberg, this lawsuit is part of an emerging pattern of similar cases against major employers such as <strong>Johnson &amp; Johnson</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and <strong>Wells Fargo &amp; Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>).</p>
<p>These cases are examining the role of employers in the escalating healthcare costs in the US and&nbsp;the profits of pharmacy benefit&nbsp;managers like CVS.</p>
<p>Also Read: <a href="https://www.benzinga.com/news/25/01/43076952/heres-the-jaw-dropping-total-jpmorgan-chase-paid-to-fight-legal-battles-over-two-years">Here&#8217;s The Jaw-Dropping Total JPMorgan Chase Paid To Fight Legal Battles Over Two Years</a></p>
<p>The lawsuit alleges that JPMorgan&nbsp;breached its fiduciary duties under&nbsp;the Employee Retirement Income Security&nbsp;Act, which regulates large employers&#8217; benefit plans. The case also highlights instances where JPMorgan&#8217;s&nbsp;plan from CVS Health had&nbsp;significantly&nbsp;higher prices than what patients&nbsp;would pay without insurance.</p>
<p>As of now, JPMorgan has not responded to requests for comment, and a CVS spokesperson declined to comment. The case,&nbsp;Seth Stern et al v.&nbsp;JPMorgan Chase &amp; Co. et al, 25-cv-02097, has been&nbsp;filed in the Southern District&nbsp;of New York.</p>
<p><strong>Why It Matters:</strong>&nbsp;This lawsuit underscores the ongoing debate about the role of employers and pharmacy benefit managers in the rising costs of healthcare in the US. </p>
<p>The outcome of this case could potentially influence how other companies manage their employee health benefits, particularly in relation to prescription drug costs. </p>
<p>It also raises questions about the transparency and fairness of pricing in the pharmaceutical industry.</p>
<p>Read Next</p>
<p><a href="https://www.benzinga.com/news/23/11/35865043/us-banks-are-abruptly-freezing-accounts-heres-how-you-can-save-yours" target="_blank" rel="noreferrer noopener"><strong>US Banks Are Abruptly Freezing Accounts — Here's How You Can Save Yours</strong></a></p>
<p>Image: Shutterstock</p>


Allegations of Inflated Prescription Drug Costs Spark Employee Lawsuit Against JPMorgan

<p>On Friday, <strong>CVS Health&nbsp;Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) released data from the CVS Weight Management&nbsp;program, in which participants achieved more than 15% weight loss on average. This included existing anti-obesity medication users who succeeded in nearly doubling their pre-program weight loss while working with program clinicians <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">on diet and lifestyle</a>.</p>
<p>Results are derived from a population of 265,000 members from 2023-2024.&nbsp;</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43709040/cvs-health-gains-momentum-after-q4-performance-analyst-upgrades-stock" rel="noreferrer noopener">CVS Health Gains Momentum After Q4 Performance, Analyst Upgrades Stock</a></strong></p>
<p>The initial results demonstrate improved weight loss and high program satisfaction for CVS Caremark clients&#8217; plan members trying a lifestyle-first approach, as well as additional clinical effectiveness and cost savings for members receiving clinical support while taking weight management <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44324587/cvs-weight-management-program-improves-health-outcomes-while-also-lowering-costs" rel="noreferrer noopener">medications like GLP-1s</a>.</p>
<p>GLP-1 products from <strong>Novo Nordisk A/S</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and <strong>Eli Lilli And Co </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) have gained substantial traction. The CVS Weight Management program provides one-on-one support from a dedicated registered dietitian in a virtual setting, including personalized nutrition planning.</p>
<p>The program can integrate into a member&#8217;s existing pharmacy benefit with plan sponsors&#8217; direction.</p>
<p>CVS Caremark clients who adopted the CVS Weight Management program spent up to 26% less on&nbsp;GLP-1&nbsp;medications for weight loss than clients who did not adopt the program.</p>
<p>The program also has a lasting impact, with 92% of participating plan members expressing satisfaction after six months.</p>
<p>As of&nbsp;February 1, 2025, the CVS Weight Management program is now available to over 3.5 million CVS Caremark plan members.</p>
<p>Despite FDA prescription drug labeling recommendations to take&nbsp;GLP-1&#8217;s in combination with diet and physical activity, 70% of members were using a weight management drug without any lifestyle or nutrition support before enrolling in the CVS Weight Management program.</p>
<ul>
<li>Before program enrollment, nearly 30% of members had lost less than 1% of their body weight on anti-obesity medication. These same members lost, on average, 11.7% of body weight after enrollment.</li>
<li>The program accelerated weight loss and delivered an average of 20% weight loss for those with moderate success before enrollment.</li>
<li>Members who chose to discontinue anti-obesity medication and retain lifestyle support maintained 94% of their weight loss after 6 months.</li>
</ul>
<p><strong>Price Action:</strong> CVS stock is up 1.33% at $66.64&nbsp;at the last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/25/03/44313315/perspective-therapeutics-cancer-focused-radiotherapy-portfolio-has-upside-potentional-says-analyst" target="_blank" rel="noreferrer noopener">Perspective Therapeutics&#8217; Cancer-Focused Radiotherapy Portfolio Has Upside Potential, Says Analyst</a></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants

CVS Health Reports Results From CVS Weight Management Program With 15% Average Weight Loss, Including Significant Gains For Anti-Obesity Medication Users

<p>Deep-pocketed investors have adopted a bearish approach towards CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for CVS Health. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 30% leaning bullish and 61% bearish. Among these notable options, 10 are puts, totaling $2,588,137, and 3 are calls, amounting to $316,330.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $65.0 to $70.0 for CVS Health during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in CVS Health's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to CVS Health's substantial trades, within a strike price spectrum from $65.0 to $70.0 over the preceding 30 days.</p>
<h3>CVS Health Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741893358_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$10.85</td>
<td>$9.25</td>
<td>$10.3</td>
<td>$67.50</td>
<td>$2.0M</td>
<td>38</td>
<td>2.0K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.6</td>
<td>$2.55</td>
<td>$2.6</td>
<td>$67.50</td>
<td>$259.7K</td>
<td>8.6K</td>
<td>84</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.65</td>
<td>$4.55</td>
<td>$4.6</td>
<td>$65.00</td>
<td>$103.5K</td>
<td>4.3K</td>
<td>1.1K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$11.6</td>
<td>$11.15</td>
<td>$11.6</td>
<td>$67.50</td>
<td>$90.4K</td>
<td>12</td>
<td>78</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.65</td>
<td>$65.00</td>
<td>$85.1K</td>
<td>4.3K</td>
<td>503</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<p>In light of the recent options history for CVS Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is CVS Health Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,011,865, with CVS's price up by 1.02%, positioned at $65.5.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<h3>Professional Analyst Ratings for CVS Health</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $75.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on CVS Health, which currently sits at a price target of $81.<br />
&#x2A; Showing optimism, an analyst from Leerink Partners upgrades its rating to Outperform with a revised price target of $75.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on CVS Health, maintaining a target price of $76.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on CVS Health, which currently sits at a price target of $73.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on CVS Health, maintaining a target price of $73. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for CVS Health with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Spotlight on CVS Health: Analyzing the Surge in Options Activity

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.</p>
<h3 class="wp-block-heading"><strong>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 4.01%</li>
<li><strong>Truist Securities </strong>analyst David Macdonald maintained a Buy rating and raised the price target from $60 to $76 on Feb. 13, 2025. This analyst has an accuracy rate of 65%.</li>
<li><strong>Leerink Partners </strong>analyst Michael Cherny upgraded the stock from Market Perform to Outperform and boosted the price target from $55 to $75 on Feb. 13, 2025. This analyst has an accuracy rate of 61%.</li>
<li><strong>Recent News:</strong> On March 4, Wellvana and CVS Health disclosed that Wellvana has acquired the Medicare Shared Savings Program business of CVS Accountable Care&#x2122;, part of CVS Health, in an all-stock transaction.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">CVS news</a>. </li>
</ul>
<p><figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/59c9cf91-f220-445e-9cc8-fb8e60e12227" alt="" style="width:620px;height:auto" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield:</strong> 4.06%</li>
<li><strong>Wells Fargo </strong>analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 74%.</li>
<li><strong>Citigroup </strong>analyst Andrew Baum maintained a Neutral rating and boosted the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 72%.</li>
<li><strong>Recent News:</strong> On March 7, the European Commission (EC) approved Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC), a type of liver cancer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43.png" alt="" class="wp-image-815700" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43-768x701.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</strong></h3>
<ul>
<li><strong>Dividend Yield: </strong>2.98%</li>
<li><strong>Guggenheim </strong>analyst Vamil Divan maintained a Neutral rating and raised the price target from $162 to $166 on Feb. 3, 2025. This analyst has an accuracy rate of 76%.</li>
<li><strong>Barclays </strong>analyst Matt Miksic maintained an Equal-Weight rating and increased the price target from $159 to $166 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li><strong>Recent News: </strong>On March 7, Johnson &amp; Johnson decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for major depressive disorder (aMDD).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">latest JNJ news</a> </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44.png" alt="" class="wp-image-815702" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44-768x702.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure></p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></strong></li>
</ul>


<p><strong>CVS Health's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has risen 10.0% since its last report. The company recently reported that it has <strong>23.60 million shares sold short</strong>, which is 1.87% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.74 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741293029_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for CVS Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 9.80%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


<p>Financial giants have made a conspicuous bullish move on CVS Health. Our analysis of options history for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 62% of traders were bullish, while 12% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $451,894, and 3 were calls, valued at $464,288.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $62.5 and $75.0 for CVS Health, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in CVS Health's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to CVS Health's substantial trades, within a strike price spectrum from $62.5 to $75.0 over the preceding 30 days.</p>
<h3>CVS Health Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741274197_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.97</td>
<td>$1.65</td>
<td>$1.77</td>
<td>$67.50</td>
<td>$301.7K</td>
<td>6.9K</td>
<td>2.2K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$10.65</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$75.00</td>
<td>$189.2K</td>
<td>183</td>
<td>182</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$62.50</td>
<td>$137.4K</td>
<td>2.3K</td>
<td>0</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.78</td>
<td>$1.74</td>
<td>$1.74</td>
<td>$67.50</td>
<td>$90.0K</td>
<td>6.9K</td>
<td>38</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$7.9</td>
<td>$6.5</td>
<td>$7.25</td>
<td>$67.50</td>
<td>$72.5K</td>
<td>1.5K</td>
<td>100</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<p>In light of the recent options history for CVS Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>CVS Health's Current Market Status</h3>
<ul>
<li>Trading volume stands at 592,345, with CVS's price down by -2.03%, positioned at $64.61.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 55 days.</li>
</ul>
<h3>Professional Analyst Ratings for CVS Health</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $75.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on CVS Health, maintaining a target price of $73.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on CVS Health, maintaining a target price of $76.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for CVS Health, targeting a price of $81.<br />
&#x2A; Showing optimism, an analyst from Leerink Partners upgrades its rating to Outperform with a revised price target of $75.<br />
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on CVS Health, maintaining a target price of $73. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for CVS Health, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CVS Health Options Trading: A Deep Dive into Market Sentiment

<p>With latest transaction, Wellvana supports primary care providers across 40 states, serving approximately 1 million patients.</p>
<p>NASHVILLE, Tenn., and WOONSOCKET, R.I., March 4, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4375063-1&amp;h=266419207&amp;u=http%3A%2F%2Fwww.wellvana.com%2F&amp;a=Wellvana">Wellvana</a> and CVS Health&#xAE; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) today announced that Wellvana has acquired the Medicare Shared Savings Program (MSSP) business of CVS Accountable Care&#x2122;, part of CVS Health, in an all-stock transaction, giving CVS Health a strategic minority investment in Wellvana.&nbsp;</p>


Asset Sales

CVS Health Announces That Wellvana Has Acquired The Medicare Shared Savings Program Business Of CVS Accountable Care, Part Of CVS Health, In An All-Stock Transaction; Detailed Terms Have Not Been Disclosed

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>CVS Health</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CVS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for CVS Health.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $243,252, and 6 are calls, for a total amount of $485,932.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $70.0 for CVS Health, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CVS Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CVS Health's significant trades, within a strike price range of $50.0 to $70.0, over the past month.</p>
<h3>CVS Health Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740767456_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$16.35</td>
<td>$16.15</td>
<td>$16.15</td>
<td>$50.00</td>
<td>$161.5K</td>
<td>327</td>
<td align="right">100</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$7.5</td>
<td>$7.35</td>
<td>$7.35</td>
<td>$62.50</td>
<td>$154.3K</td>
<td>167</td>
<td align="right">212</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.25</td>
<td>$3.15</td>
<td>$3.15</td>
<td>$62.50</td>
<td>$90.7K</td>
<td>2.2K</td>
<td align="right">1</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$67.50</td>
<td>$77.3K</td>
<td>1.2K</td>
<td align="right">0</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.15</td>
<td>$6.9</td>
<td>$7.15</td>
<td>$67.50</td>
<td>$62.2K</td>
<td>1.4K</td>
<td align="right">89</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<h3>Current Position of CVS Health</h3>
<ul>
<li>With a volume of 4,111,017, the price of CVS is down -0.47% at $64.18. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 61 days.</li>
</ul>
<h3>What The Experts Say On CVS Health</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $75.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on CVS Health, which currently sits at a price target of $76.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on CVS Health, maintaining a target price of $73.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for CVS Health, targeting a price of $81.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on CVS Health, which currently sits at a price target of $73.<br />
&#x2A; Showing optimism, an analyst from Leerink Partners upgrades its rating to Outperform with a revised price target of $75. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CVS Health options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Looking At CVS Health's Recent Unusual Options Activity

<p>Financial giants have made a conspicuous bearish move on CVS Health. Our analysis of options history for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 30% of traders were bullish, while 70% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $138,985, and 7 were calls, valued at $321,467.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $80.0 for CVS Health over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CVS Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CVS Health's significant trades, within a strike price range of $60.0 to $80.0, over the past month.</p>
<h3>CVS Health Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740597409_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.37</td>
<td>$1.33</td>
<td>$1.33</td>
<td>$72.50</td>
<td>$114.3K</td>
<td>1.6K</td>
<td align="right">139</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.9</td>
<td>$5.85</td>
<td>$5.86</td>
<td>$60.00</td>
<td>$58.6K</td>
<td>4.1K</td>
<td align="right">100</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$5.3</td>
<td>$5.15</td>
<td>$5.15</td>
<td>$80.00</td>
<td>$51.5K</td>
<td>463</td>
<td align="right">102</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.35</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$75.00</td>
<td>$47.5K</td>
<td>545</td>
<td align="right">36</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.7</td>
<td>$8.45</td>
<td>$8.6</td>
<td>$62.50</td>
<td>$36.1K</td>
<td>2.4K</td>
<td align="right">199</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<p>After a thorough review of the options trading surrounding CVS Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>CVS Health's Current Market Status</h3>
<ul>
<li>Trading volume stands at 3,288,419, with CVS's price down by -0.44%, positioned at $63.38.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 63 days.</li>
</ul>
<h3>What Analysts Are Saying About CVS Health</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $75.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on CVS Health, which currently sits at a price target of $73.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for CVS Health, targeting a price of $81.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for CVS Health, targeting a price of $73.<br />
&#x2A; An analyst from Leerink Partners upgraded its action to Outperform with a price target of $75.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on CVS Health, maintaining a target price of $76. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for CVS Health, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Behind the Scenes of CVS Health's Latest Options Trends

<p>Financial giants have made a conspicuous bearish move on CVS Health. Our analysis of options history for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 25% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $282,069, and 2 were calls, valued at $56,340.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $65.0 for CVS Health over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for CVS Health's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CVS Health's whale trades within a strike price range from $50.0 to $65.0 in the last 30 days. </p>
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740153631_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$0.84</td>
<td>$0.6</td>
<td>$0.84</td>
<td>$64.00</td>
<td>$100.9K</td>
<td>703</td>
<td align="right">102</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.6</td>
<td>$5.25</td>
<td>$5.6</td>
<td>$65.00</td>
<td>$43.6K</td>
<td>2.7K</td>
<td align="right">0</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$7.1</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$65.00</td>
<td>$35.9K</td>
<td>2.7K</td>
<td align="right">0</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.57</td>
<td>$0.5</td>
<td>$0.57</td>
<td>$60.00</td>
<td>$35.2K</td>
<td>6.8K</td>
<td align="right">6</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.0</td>
<td>$3.85</td>
<td>$3.95</td>
<td>$62.50</td>
<td>$34.3K</td>
<td>873</td>
<td align="right">265</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<p>Following our analysis of the options activities associated with CVS Health, we pivot to a closer look at the company's own performance.</p>
<h3>CVS Health's Current Market Status</h3>
<ul>
<li>With a volume of 4,301,321, the price of CVS is down -1.51% at $64.11. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 68 days.</li>
</ul>
<h3>What The Experts Say On CVS Health</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $75.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Leerink Partners upgraded its action to Outperform with a price target of $75.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on CVS Health, maintaining a target price of $73.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on CVS Health, which currently sits at a price target of $73.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for CVS Health, targeting a price of $81.<br />
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for CVS Health, targeting a price of $76. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CVS Health options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Press Releases

Twentyeight Health and Aetna Better Health® of Illinois Collaborate to Expand Member Access to Sexual and Reproductive Telehealth Services

Earnings

CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2024 RESULTS

Ed DeVaney named President of CVS Caremark

Thermo Fisher Scientific Elects New Director to Board

CVS Pharmacy® introduces enhanced flu testing and treatment offerings

Wellvana acquires CVS Health's MSSP business

CVS Health Foundation helps address barriers to care and provides resources for individuals with chronic health conditions in Hartford

CVS Weight Management™ Program Improves Health Outcomes While Also Lowering Costs

CVS Health declares quarterly dividend

CVS Health to hold first quarter 2025 earnings conference call

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

CVS Health

空売り

CVS Health (NYSE:CVS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル